Fate Therapeutics Inc FATE

NAS: FATE | ISIN: US31189P1021   3/05/2024
4,060 USD (-0,98%)
(-0,98%)   3/05/2024

2 maart 2023 · FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

9 februari 2023 · FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

1 februari 2023 · Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate · Persbericht

28 januari 2023 · INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE · Persbericht

8 maart 2021 · Fate Therapeutics to Present at Upcoming Investor Conferences · Persbericht

24 februari 2021 · Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress · Persbericht

22 februari 2021 · Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference · Persbericht

19 februari 2021 · Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results · Persbericht

8 januari 2021 · Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares · Persbericht

6 januari 2021 · Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants · Persbericht

4 januari 2021 · Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock · Persbericht

Mijn selecties